TMDX— AI Stock Forecast & Price Targets
Published 7/24/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live TMDX price forecast →
TMDX is a category-leading organ preservation platform with elite quality metrics (45% ROE, 59% gross margins) trading at $71.13 after a ~54% drawdown from $156, but Q1 2026's operating margin collapse to 7.6% and FCF flip to -$12M raise legitimate structural concerns. The Aug 4 earnings print (~11 days out) is the binary catalyst that will resolve whether Q1 was one-time capex/ramp drag or a durable margin reset — until then, holding is the correct posture with no sizing into the print.
HOLD into the Aug 4 earnings print (~11 days). Do NOT initiate a new position or size up ahead of a binary event with 23.7% short float and 100% retail bullish sentiment — that combination is either a squeeze setup or a capitulation setup, and there's no edge in guessing. If already long, keep size trimmed. Key levels: $65 is hard invalidation for the bull case (weekly close below opens $55-$58); $80 is the level where the trend can be argued to have shifted. The earnings print itself is the invalidation event — a Q2 operating margin below 10% and continued negative FCF would confirm structural damage.
1-6 month view hinges entirely on the Aug 4 print. Bull scenario: Q2 op margin recovers to 15%+ with FCF flip positive, guidance reaffirmed at $727-$757M — stock can retrace to $90-$100. Base scenario: Q2 shows modest sequential improvement (10-13% op margin) but FCF still negative, stock grinds to $78-$85 as skepticism persists. Bear scenario: Q2 confirms sub-10% op margins with lowered guidance — stock breaks $60 toward $50-$55. Expected return range from $71 is roughly -25% to +30% over 6 months, skewed slightly to the downside given the recent trajectory. Would change my mind: two consecutive quarters of sequential operating margin improvement AND positive FCF would flip me to ACCUMULATE.
1-3 year terminal thesis remains intact IF the current capex cycle produces the operating leverage promised. TMDX has genuine platform moat in organ preservation, NOP logistics network creates recurring revenue layer, European expansion (Italy/Germany/PAD Aviation) opens a $2B+ TAM, and OCS Kidney launch (late 2026/early 2027) diversifies away from ~80% liver concentration. If they execute, this is a $150-$200 stock over 3 years. Biggest structural risk is CMS/payer reimbursement policy shifts — an existential, unhedgeable threat that could compress the entire unit economics of OCS. Secondary structural risk is competitor clearance eating into the liver franchise before diversification lands.
Revenue trajectory remains strong at $635.9M TTM with 30.2% Y/Y growth and 21.2% Q/Q, and the underlying franchise economics are elite — 58.8% gross margin, 45.2% ROE, 27% profit margin. However, the sequential margin trajectory is deteriorating meaningfully: operating margin collapsed from 23.2% in Q2 2025 to 16.2% in Q3, 13.2% in Q4, and 7.6% in Q1 2026 — a four-quarter sequential compression that cannot be dismissed as noise. FCF flipped from +$82.5M in Q2 2025 to -$12.1M in Q1 2026 as capex ramped from $9M to $36.7M quarterly. Balance sheet reflects the debt-funded expansion: total debt jumped from $519M to $863M in Q1 2026 (D/E 1.75), though $461.7M cash and 6.74x current ratio provide runway. Net income of $7.3M in Q1 was inflated by prior quarters (Q4's $105M included non-recurring items), so the -71% EPS Q/Q print is the honest signal. Capital allocation is a bet: management is levering the balance sheet to build NOP logistics capacity ahead of demand, which either produces massive operating leverage on ramp or leaves them structurally over-built.
Structurally broken across timeframes. Weekly chart shows a decisive breakdown from $175 highs to a $60-$75 range, with price currently at $71.13 sitting -35.5% below the 200-day SMA and -46.8% over the past 6 months. Daily chart shows price pinned near $70-$72 support after a failed rally attempt in early July, with the recent -6.4% weekly performance and 'lost the 50dma' retail chatter confirming near-term weakness. The 1h and 4h charts show consolidation in the $68-$75 zone with no momentum divergence. RSI at 45.4 is neutral, SMA20 -1.1% and SMA50 +0.15% show price is mean-reverting inside a lower range. The model's forecast band projecting a spike to $95-$114 across timeframes is not credible given the 1wk directional accuracy of 17% (well below the 67% naive baseline) — this forecast should be heavily discounted. Key levels: $65 (52-week low zone) is critical support; $80 is first meaningful resistance, then $90-$95. A weekly close below $65 opens the door to $55-$58.
The news flow is a mix of analyst reiterations and cautious skepticism ahead of the Aug 4 print. Evercore ISI cut its target from $100 to $90 (still Outperform) on July 6, while TD Cowen maintained a $120 target (Buy) on July 1 — the divergence reflects genuine uncertainty. Two Motley Fool pieces frame TMDX as a 'buy the dip' opportunity given the ~45% drawdown, and Seeking Alpha explicitly argues 'the margins must recover' — signaling the sell-side consensus knows margin recovery is the whole thesis. The July 6 PAD Aviation strategic investment is legitimate signal (European logistics scale-up for NOP), but is medium-term in nature. The consensus target of $114 implies ~60% upside but the CALIBRATION note is clear: prior base targets have been running ~16% optimistic. Retail sentiment is 100% bullish across a small sample, which — combined with 23.7% short float — sets up a genuinely binary reaction to earnings in either direction.
- PAD Aviation GmbH strategic investment (announced July 6) — European logistics backbone for NOP expansion, targeting pan-European rollout by 2027
- OCS Kidney platform launch scheduled late 2026/early 2027 — critical diversification away from ~80% liver revenue concentration
- $344M debt-funded NOP capacity buildout — creates operating leverage on utilization ramp (Q1 capex $36.7M vs $9M in Q2 2025)
- 2026 full-year revenue guidance of $727-$757M implies ~15-20% growth acceleration from Q1's $173.9M run-rate
- Gen 3 OCS platform updates across heart, lung, and liver — product-mix improvement supporting ASP expansion
- Q1 2026 operating margin collapsed to 7.6% from 23.2% two quarters prior — four-quarter sequential deterioration suggests structural pressure, not one-time noise
- Total debt jumped from $519M to $863M in Q1 (D/E 1.75); negative FCF (-$12M Q1) combined with rising leverage creates pressure if utilization ramp is delayed
- 23.7% short float + 100% retail bullish sentiment into a binary Aug 4 earnings event is a volatile setup in either direction
- Revenue concentration ~80% in liver segment exposes company to single-segment shocks or competitor clearance events
- Unhedgeable CMS/payer reimbursement policy risk could impair OCS unit economics structurally
- Model's own 1wk forecast has 17% directional accuracy vs 67% naive baseline — the projected upside spike to $95-$114 is not credible
- Prior base-case targets on this name have been running ~16% optimistic — discipline near $78-$85 zone is warranted
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord